SRPT Sarepta Therapeutics Inc

Price (delayed)

$117.29

Market cap

$11.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.8

Enterprise value

$11.98B

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going ...

Highlights
The company's equity has surged by 123% YoY and by 12% QoQ
SRPT's gross profit is up by 38% year-on-year and by 13% since the previous quarter
Sarepta Therapeutics's quick ratio has decreased by 30% from the previous quarter and by 11% YoY

Key stats

What are the main financial stats of SRPT
Market
Shares outstanding
93.86M
Market cap
$11.01B
Enterprise value
$11.98B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.77
Price to sales (P/S)
8.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.63
Earnings
Revenue
$1.24B
EBIT
-$520.1M
EBITDA
-$461.21M
Free cash flow
-$577.1M
Per share
EPS
-$5.8
Free cash flow per share
-$6.25
Book value per share
$9.19
Revenue per share
$13.46
TBVPS
$35.33
Balance sheet
Total assets
$3.26B
Total liabilities
$2.41B
Debt
$1.4B
Equity
$859.34M
Working capital
$1.93B
Liquidity
Debt to equity
1.63
Current ratio
3.95
Quick ratio
3.18
Net debt/EBITDA
-2.1
Margins
EBITDA margin
-37.1%
Gross margin
87.9%
Net margin
-43.1%
Operating margin
-21.5%
Efficiency
Return on assets
-17.1%
Return on equity
-69.7%
Return on invested capital
-15.8%
Return on capital employed
-19.9%
Return on sales
-41.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SRPT stock price

How has the Sarepta Therapeutics stock price performed over time
Intraday
-0.86%
1 week
-7.63%
1 month
-4.68%
1 year
-4.35%
YTD
21.63%
QTD
-9.4%

Financial performance

How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$1.24B
Gross profit
$1.09B
Operating income
-$267.82M
Net income
-$535.98M
Gross margin
87.9%
Net margin
-43.1%
SRPT's operating margin has soared by 63% YoY and by 40% from the previous quarter
SRPT's operating income has soared by 50% year-on-year and by 33% since the previous quarter
SRPT's net margin is up by 43% year-on-year and by 31% since the previous quarter
SRPT's gross profit is up by 38% year-on-year and by 13% since the previous quarter

Growth

What is Sarepta Therapeutics's growth rate over time

Valuation

What is Sarepta Therapeutics stock price valuation
P/E
N/A
P/B
12.77
P/S
8.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.63
The EPS has grown by 28% YoY and by 26% from the previous quarter
The company's equity has surged by 123% YoY and by 12% QoQ
SRPT's P/B is 10% below its last 4 quarters average of 14.2 and 3.3% below its 5-year quarterly average of 13.2
The P/S is 43% less than the 5-year quarterly average of 15.2 and 12% less than the last 4 quarters average of 9.9
The revenue rose by 33% YoY and by 13% QoQ

Efficiency

How efficient is Sarepta Therapeutics business performance
The ROS has grown by 43% YoY and by 30% from the previous quarter
The return on equity is up by 41% year-on-year and by 34% since the previous quarter
Sarepta Therapeutics's ROIC has increased by 34% YoY and by 24% from the previous quarter
The ROA has increased by 25% YoY and by 23% from the previous quarter

Dividends

What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRPT.

Financial health

How did Sarepta Therapeutics financials performed over time
The total assets is 36% more than the total liabilities
Sarepta Therapeutics's quick ratio has decreased by 30% from the previous quarter and by 11% YoY
The company's current ratio fell by 27% QoQ and by 4.4% YoY
SRPT's debt is 63% greater than its equity
The company's equity has surged by 123% YoY and by 12% QoQ
The debt to equity has dropped by 61% year-on-year and by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.